Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN AND BENZOYL PEROXIDE versus PROKLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN AND BENZOYL PEROXIDE versus PROKLAR.
ERYTHROMYCIN AND BENZOYL PEROXIDE vs PROKLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. Benzoyl peroxide has bactericidal effects against Propionibacterium acnes, likely through the release of free radical oxygen that oxidizes bacterial proteins. It also has keratolytic and comedolytic properties.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Topical: Apply a thin layer to affected areas once daily in the evening.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
Erythromycin: 1.4–2.0 hours (terminal half-life in adults). Benzoyl peroxide: Not applicable; it is a topical agent with negligible systemic absorption.
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Erythromycin is primarily excreted via bile (fecal elimination) with approximately 15% excreted unchanged in urine. Benzoyl peroxide is degraded to benzoic acid, which is conjugated with glycine to form hippuric acid and excreted renally; less than 5% is excreted unchanged in urine.
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic